Works in European Journal of Nuclear Medicine & Molecular Imaging, 2023, Vol 50, Issue 10

Results: 33

Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 2935, doi. 10.1007/s00259-023-06338-6

By:

Chakravarty, Rubel;
Song, Wenyu;
Chakraborty, Sudipta;
Cai, Weibo

Publication type:

Article

PET imaging of tumor vascular normalization in hepatocellular carcinoma.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 2940, doi. 10.1007/s00259-023-06337-7

By:

An, Shuxian;
Liu, Jianjun;
Huang, Gang;
Kang, Fei;
Wei, Weijun

Publication type:

Article

Intriguing information from recent letter and article regarding unwanted targeting of salivary glands by PSMA ligands.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 2950, doi. 10.1007/s00259-023-06325-x

By:

Huang, Steve S.;
DiFilippo, Frank;
Lindner, Daniel;
Heston, Warren D. W.

Publication type:

Article

PET/MRI in practice: a clinical centre survey endorsed by the European Association of Nuclear Medicine (EANM) and the EANM Forschungs GmbH (EARL).

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 2927, doi. 10.1007/s00259-023-06308-y

By:

Prakken, Niek H. J.;
Besson, Florent L.;
Borra, Ronald J. H.;
Büther, Florian;
Buechel, Ronny R.;
Catana, Ciprian;
Chiti, Arturo;
Dierckx, Rudi A. J. O.;
Dweck, Marc R.;
Erba, Paola A.;
Glaudemans, Andor W. J. M.;
Gormsen, Lars C.;
Hristova, Ivalina;
Koole, Michel;
Kwee, Thomas C.;
Mottaghy, Felix M.;
Polycarpou, Irene;
Prokop, Mathias;
Stegger, Lars;
Tsoumpas, Charalampos

Publication type:

Article

Correction to: EANM enabling guide: how to improve the accessibility of clinical dosimetry.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3157, doi. 10.1007/s00259-023-06304-2

By:

Gear, Jonathan;
Stokke, Caroline;
Terwinghe, Christelle;
Gnesin, Silvano;
Sandström, Mattias;
Tran‑Gia, Johannes;
Cremonesi, Marta;
Cicone, Francesco;
Verburg, Fredrik;
Hustinx, Roland;
Giovanella, Luca;
Herrmann, Ken;
Gabiña, Pablo Minguez

Publication type:

Article

Correction to: One‑stop [18F]FDG and [68Ga]Ga‑DOTA‑FAPI‑04 total‑body PET/CT examination with dual‑low activity: a feasibility study.

Published in:

2023

By:

Liu, Guobing;
Mao, Wujian;
Yu, Haojun;
Hu, Yan;
Gu, Jianying;
Shi, Hongcheng

Publication type:

Correction Notice

Response to: GCP III is not the "off-target" for urea-based PSMA-ligands.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 2947, doi. 10.1007/s00259-023-06302-4

By:

Bassi, Gabriele;
Cazzamalli, Samuele;
Oehler, Sebastian;
Lucaroni, Laura;
Georgiev, Tony;
Favalli, Nicholas;
Neri, Dario

Publication type:

Article

A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3126, doi. 10.1007/s00259-023-06283-4

By:

Wang, Guochang;
Li, Linlin;
Zhu, Ming;
Zang, Jie;
Wang, Jiarou;
Wang, Rongxi;
Yan, Weigang;
Zhu, Lin;
Kung, Hank F.;
Zhu, Zhaohui

Publication type:

Article

Development and external validation of a multivariable [68Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3137, doi. 10.1007/s00259-023-06278-1

By:

Muehlematter, Urs J.;
Schweiger, Lilit;
Ferraro, Daniela A.;
Hermanns, Thomas;
Maurer, Tobias;
Heck, Matthias M.;
Rupp, Niels J.;
Eiber, Matthias;
Rauscher, Isabel;
Burger, Irene A.

Publication type:

Article

Defining the role of nuclear medicine in haematological tumours—EANM Focus 4: consensus on molecular imaging and therapy in haematological tumours.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 2925, doi. 10.1007/s00259-023-06276-3

By:

Nanni, Cristina;
Kobe, Carsten;
Herrmann, Ken;
Kunikowska, Jolanta

Publication type:

Article

Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3050, doi. 10.1007/s00259-023-06272-7

By:

Millul, Jacopo;
Koepke, Lennart;
Haridas, Gaonkar Raghuvir;
Sparrer, Konstantin M. J.;
Mansi, Rosalba;
Fani, Melpomeni

Publication type:

Article

In vivo evaluation of a novel 18F-labeled PET radioligand for translocator protein 18 kDa (TSPO) in monkey brain.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 2962, doi. 10.1007/s00259-023-06270-9

By:

Yan, Xuefeng;
Siméon, Fabrice G.;
Liow, Jeih-San;
Morse, Cheryl L.;
Montero Santamaria, Jose A.;
Jenkins, Madeline;
Manly, Lester S.;
Van Buskirk, Maia;
Zoghbi, Sami S.;
Pike, Victor W.;
Innis, Robert B.;
Zanotti-Fregonara, Paolo

Publication type:

Article

GCP III is not the "off-target" for urea-based PSMA ligands.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 2944, doi. 10.1007/s00259-023-06265-6

By:

Lee, Zhenghong;
Heston, Warren D.;
Wang, Xinning;
Basilion, James P.

Publication type:

Article

Biodistribution and radiation dosimetry in cancer patients of the ascorbic acid analogue 6-Deoxy-6-[18F] fluoro-L-ascorbic acid PET imaging: first-in-human study.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3072, doi. 10.1007/s00259-023-06262-9

By:

Long, Yali;
Yi, Chang;
Wu, Renbo;
Zhang, Yuying;
Zhang, Bing;
Shi, Xinchong;
Zhang, Xiangsong;
Zha, Zhihao

Publication type:

Article

Molecular imaging phenotyping of germline fumarate hydratase (FH) pathogenic variant-positive metastatic pheochromocytoma.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3155, doi. 10.1007/s00259-023-06261-w

By:

Imperiale, Alessio;
Pepponi, Miriam;
Poterszman, Nathan;
Jha, Abhishek;
Collen, Cedric;
Brumaru, Daniel;
Chenard, Marie-Pierre;
Taïeb, David;
Pacak, Karel;
Goichot, Bernard

Publication type:

Article

Preclinical evaluation of 68Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 2952, doi. 10.1007/s00259-023-06260-x

By:

Cai, Huawei;
Li, Zhao;
Shi, Qiuxiao;
Yang, Hao;
Xiao, Liu;
Li, Mufeng;
Lin, Hua;
Wu, Xiaoai;
She, Tianshan;
Chen, Lihong;
Li, Lin;
Lu, Xiaofeng

Publication type:

Article

A machine learning method integrating ECG and gated SPECT for cardiac resynchronization therapy decision support.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3022, doi. 10.1007/s00259-023-06259-4

By:

de A. Fernandes, Fernando;
Larsen, Kristoffer;
He, Zhuo;
Nascimento, Erivelton;
Peix, Amalia;
Sha, Qiuying;
Paez, Diana;
Garcia, Ernest V.;
Zhou, Weihua;
Mesquita, Claudio T.

Publication type:

Article

Melanin-targeted [18F]-PFPN PET imaging for prognosticating patients with melanoma.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3062, doi. 10.1007/s00259-023-06258-5

By:

Zhang, Xiao;
Lin, Zhaoguo;
Li, Mengting;
Gai, Yongkang;
Zheng, Huaiyuan;
Fan, Li;
Ruan, Weiwei;
Hu, Fan;
Chen, Jing;
Lan, Xiaoli

Publication type:

Article

The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with 177Lu DOTATATE (LuTate).

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 2997, doi. 10.1007/s00259-023-06257-6

By:

Alipour, R.;
Jackson, P.;
Bressel, M.;
Hogg, A.;
Callahan, J.;
Hicks, R. J.;
Kong, G.

Publication type:

Article

Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3034, doi. 10.1007/s00259-023-06256-7

By:

Geist, Barbara Katharina;
Brath, Helmut;
Zisser, Lucia;
Yu, Josef;
Fueger, Barbara;
Nics, Lukas;
Patronas, Eva Maria;
Kautzky-Willer, Alexandra;
Hacker, Marcus;
Rasul, Sazan

Publication type:

Article

Machine learning identifies multi-parametric functional PET/MR imaging cluster to predict radiation resistance in preclinical head and neck cancer models.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3084, doi. 10.1007/s00259-023-06254-9

By:

Boeke, Simon;
Winter, René M.;
Leibfarth, Sara;
Krueger, Marcel A.;
Bowden, Gregory;
Cotton, Jonathan;
Pichler, Bernd J.;
Zips, Daniel;
Thorwarth, Daniela

Publication type:

Article

A pharmacological imaging challenge based on 11C-buprenorphine PET-MRI to explore the response to opioids in humans.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3153, doi. 10.1007/s00259-023-06253-w

By:

Leroy, Claire;
Goutal, Sébastien;
Breuil, Louise;
Gervais, Philippe;
Cherkaoui, Hamza;
Ciuciu, Philippe;
Auvity, Sylvain;
Vodovar, Dominique;
Comtat, Claude;
Lebon, Vincent;
Bottlaender, Michel;
Tournier, Nicolas

Publication type:

Article

The predictive value of pretherapy [68Ga]Ga-DOTA-TATE PET and biomarkers in [177Lu]Lu-PRRT tumor dosimetry.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 2984, doi. 10.1007/s00259-023-06252-x

By:

Akhavanallaf, Azadeh;
Peterson, Avery B.;
Fitzpatrick, Kellen;
Roseland, Molly;
Wong, Ka Kit;
El-Naqa, Issam;
Zaidi, Habib;
Dewaraja, Yuni K.

Publication type:

Article

Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3107, doi. 10.1007/s00259-023-06251-y

By:

Zhou, Xiang;
Hu, Yongquan;
Sun, Hong;
Chen, Ruohua;
Huang, Gang;
Liu, Jianjun

Publication type:

Article

Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3116, doi. 10.1007/s00259-023-06248-7

By:

Zhu, Wenjia;
Li, Xiaoyuan;
Zheng, Guoyang;
Bai, Chunmei;
Ji, Zhigang;
Zhang, Haiqiong;
Xing, Haiqun;
Zhang, Yushi;
Huo, Li

Publication type:

Article

FAP expression in alpha cells of Langherhans insulae—implications for FAPI radiopharmaceuticals' use.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3042, doi. 10.1007/s00259-023-06246-9

By:

Kirienko, Margarita;
Centonze, Giovanni;
Sabella, Giovanna;
Sollai, Mauro;
Sollini, Martina;
Lan, Xiaoli;
Chen, Haojun;
Terracciano, Luigi;
Seregni, Ettore;
Milione, Massimo

Publication type:

Article

Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3011, doi. 10.1007/s00259-023-06245-w

By:

Kosmala, Aleksander;
Serfling, Sebastian E.;
Michalski, Kerstin;
Lindner, Thomas;
Schirbel, Andreas;
Higuchi, Takahiro;
Hartrampf, Philipp E.;
Derlin, Thorsten;
Buck, Andreas K.;
Weich, Alexander;
Werner, Rudolf A.

Publication type:

Article

Radiopharmaceutical need between the clinic and regulatory agencies: how philosophy could explain 'the road taken'.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 2921, doi. 10.1007/s00259-023-06244-x

By:

Boschi, Stefano;
Todde, Sergio

Publication type:

Article

Metastatic melanoma extending along the inferior vena cava to its branches and venous plexus: a rare route metastasis characterized by [18F]FDG PET/CT.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3149, doi. 10.1007/s00259-023-06238-9

By:

Zhou, Wenlan;
Li, Xiangzhao;
Wu, Hubing

Publication type:

Article

Sarcoidosis mimicking nodal manifestations of marginal zone lymphoma.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3151, doi. 10.1007/s00259-023-06237-w

By:

Enke, Johanna S.;
Reitsam, Nic G.;
Schaller, Tina;
Claus, Rainer;
Lapa, Constantin;
Dierks, Alexander

Publication type:

Article

Bladder paraganglioma detection with [18F]MFBG PET/CT: a superior alternative to [68Ga]Ga-DOTATATE.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3147, doi. 10.1007/s00259-023-06233-0

By:

Wang, Peipei;
Li, Tuo;
Li, Fang;
Zhang, Jingjing;
Jing, Hongli

Publication type:

Article

[18F]MFBG PET/CT outperforming [123I]MIBG SPECT/CT in the evaluation of neuroblastoma.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 3097, doi. 10.1007/s00259-023-06221-4

By:

Wang, Peipei;
Li, Tuo;
Liu, Zhikai;
Jin, Mei;
Su, Yan;
Zhang, Jingjing;
Jing, Hongli;
Zhuang, Hongming;
Li, Fang

Publication type:

Article

The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients.

Published in:

European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 10, p. 2971, doi. 10.1007/s00259-023-06240-1

By:

Mauguen, Audrey;
Grewal, Ravinder K.;
Augensen, Finn;
Abusamra, Murad;
Mahajan, Sonia;
Jayaprakasam, Vetri Sudar;
Osborne, Joseph;
Haque, Sofia;
Wong, Bernadette Z. Y.;
Ghossein, Ronald A.;
Fagin, James;
Schӧder, Heiko;
Tuttle, R. Michael;
Ho, Alan;
Humm, John L.;
Larson, Steven M.

Publication type:

Article

Works in European Journal of Nuclear Medicine & Molecular Imaging, 2023, Vol 50, Issue 10

Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?

PET imaging of tumor vascular normalization in hepatocellular carcinoma.

Intriguing information from recent letter and article regarding unwanted targeting of salivary glands by PSMA ligands.

PET/MRI in practice: a clinical centre survey endorsed by the European Association of Nuclear Medicine (EANM) and the EANM Forschungs GmbH (EARL).

Correction to: EANM enabling guide: how to improve the accessibility of clinical dosimetry.

Correction to: One‑stop [<sup>18</sup>F]FDG and [<sup>68</sup>Ga]Ga‑DOTA‑FAPI‑04 total‑body PET/CT examination with dual‑low activity: a feasibility study.

Response to: GCP III is not the "off-target" for urea-based PSMA-ligands.

A prospective head-to-head comparison of [<sup>68</sup>Ga]Ga-P16-093 and [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer.

Development and external validation of a multivariable [<sup>68</sup>Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer.

Defining the role of nuclear medicine in haematological tumours—EANM Focus 4: consensus on molecular imaging and therapy in haematological tumours.

Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides.

In vivo evaluation of a novel <sup>18</sup>F-labeled PET radioligand for translocator protein 18 kDa (TSPO) in monkey brain.

GCP III is not the "off-target" for urea-based PSMA ligands.

Biodistribution and radiation dosimetry in cancer patients of the ascorbic acid analogue 6-Deoxy-6-[<sup>18</sup>F] fluoro-L-ascorbic acid PET imaging: first-in-human study.

Molecular imaging phenotyping of germline fumarate hydratase (FH) pathogenic variant-positive metastatic pheochromocytoma.

Preclinical evaluation of <sup>68</sup>Ga-radiolabeled trimeric affibody for PDGFRβ-targeting PET imaging of hepatocellular carcinoma.

A machine learning method integrating ECG and gated SPECT for cardiac resynchronization therapy decision support.

Melanin-targeted [<sup>18</sup>F]-PFPN PET imaging for prognosticating patients with melanoma.

The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with <sup>177</sup>Lu DOTATATE (LuTate).

Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus.

Machine learning identifies multi-parametric functional PET/MR imaging cluster to predict radiation resistance in preclinical head and neck cancer models.

A pharmacological imaging challenge based on <sup>11</sup>C-buprenorphine PET-MRI to explore the response to opioids in humans.

The predictive value of pretherapy [<sup>68</sup>Ga]Ga-DOTA-TATE PET and biomarkers in [<sup>177</sup>Lu]Lu-PRRT tumor dosimetry.

Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma.

Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma.

FAP expression in alpha cells of Langherhans insulae—implications for FAPI radiopharmaceuticals' use.

Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors.

Radiopharmaceutical need between the clinic and regulatory agencies: how philosophy could explain 'the road taken'.

Metastatic melanoma extending along the inferior vena cava to its branches and venous plexus: a rare route metastasis characterized by [<sup>18</sup>F]FDG PET/CT.

Sarcoidosis mimicking nodal manifestations of marginal zone lymphoma.

Bladder paraganglioma detection with [<sup>18</sup>F]MFBG PET/CT: a superior alternative to [<sup>68</sup>Ga]Ga-DOTATATE.

[<sup>18</sup>F]MFBG PET/CT outperforming [<sup>123</sup>I]MIBG SPECT/CT in the evaluation of neuroblastoma.

The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients.